

DATA SHEET

REAGENT SARS-CoV-2 isolate - Kappa (B.1.617.1 lineage) - **infectious**

REPOSITORY REFERENCE 101032

LOT NUMBER 29092021

DESCRIPTION Passage 4 Kappa isolate grown in the Vero/hSLAM cell line. Originally isolated and passaged in the Vero/hSLAM cell line by UKHSA. Mycoplasma undetectable, sterility checked.

TCID50/mL in VeroE6: 1.14 x 1e6

PROVIDED 1mL of clarified culture supernatant

SEQUENCE

In blue are Kappa defining mutations (<https://outbreak.info>). All mutations are present. Details about the sequencing protocol is available on request.

Position (NC_045512.2)	Ref	Alt	Proportion	Gene	HGVSp
71	C	A	0.01603555	CHR_START-ORF1ab	N/A
210	G	T	0.9991795	CHR_START-ORF1ab	N/A
241	C	T	0.998723	CHR_START-ORF1ab	N/A
311	C	T	0.0184456	ORF1ab	p.Leu16Phe
3037	C	T	0.9986535	ORF1ab	p.Phe924Phe
3457	C	T	0.9994635	ORF1ab	p.Tyr1064Tyr
4956	A	C	0.9996075	ORF1ab	p.Glu1564Ala
4965	C	T	0.999457	ORF1ab	p.Thr1567Ile
5578	G	T	0.999742	ORF1ab	p.Met1771Ile
7165	C	T	0.9994515	ORF1ab	p.Thr2300Thr
8551	T	A	0.0132646	ORF1ab	p.Gly2762Gly
9502	C	T	0.01220075	ORF1ab	p.Ala3079Ala
9852	A	G	0.0725813	ORF1ab	p.Asp3196Gly
10341	C	T	0.0453734	ORF1ab	p.Pro3359Leu
10875	A	C	0.0188317	ORF1ab	p.Asn3537Thr
11201	A	G	0.9773625	ORF1ab	p.Thr3646Ala
11348	A	C	0.0143355	ORF1ab	p.Met3695Leu
12854	C	T	0.1099785	ORF1ab	p.Pro4197Ser
13046	C	G	0.01083365	ORF1ab	p.Pro4261Ala
13048	T	A	0.0103668	ORF1ab	p.Pro4261Pro
13049	G	C	0.0104449	ORF1ab	p.Ala4262Pro
13051	C	A	0.0110934	ORF1ab	p.Ala4262Ala
13170	C	T	0.02479855	ORF1ab	p.Thr4302Ile
14408	C	T	0.9996195	ORF1ab	p.Pro4715Leu
15338	T	C	0.0522746	ORF1ab	p.Met5025Thr
17523	G	T	0.999077	ORF1ab	p.Met5753Ile

User Ref: 101032	Version: 1.0	Version Date: 07/02/2022
Latest version of document available at: Q-DOCS		Date Printed: 17/02/2022 16:17
Document ID: 9230	Page 1 of 4	Issue Status: Published

Position (NC_045512.2)	Ref	Alt	Proportion	Gene	HGVSp
18051	A	G	0.08140725	ORF1ab	p.Val5929Val
19126	A	G	0.6895985	ORF1ab	p.Ile6288Val
20396	A	G	0.999222	ORF1ab	p.Lys6711Arg
21137	A	G	0.9996285	ORF1ab	p.Lys6958Arg
21987	G	A	0.990969	S	p.Gly142Asp
21990	TTTA	T	0.9927145	S	p.Tyr145del
22022	G	A	0.9989535	S	p.Glu154Lys
22917	T	G	0.9994545	S	p.Leu452Arg
23012	G	C	0.9996995	S	p.Glu484Gln
23403	A	G	0.999306	S	p.Asp614Gly
23525	C	T	0.02061095	S	p.His655Tyr
23589	C	T	0.0261474	S	p.Thr676Ile
23604	C	G	0.999426	S	p.Pro681Arg
23606	C	T	0.0158647	S	p.Arg682Trp
23766	C	T	0.6013145	S	p.Ser735Leu
24775	A	T	0.999232	S	p.Gln1071His
24863	C	G	0.999135	S	p.His1101Asp
25469	C	T	0.9996245	ORF3a	p.Ser26Leu
26654	G	GT	0.0105204	M	p.Leu46fs
27299	T	C	0.9986635	ORF6	p.Ile33Thr
27610	C	T	0.999486	ORF7a	p.His73Tyr
27638	T	C	0.9992805	ORF7a	p.Val82Ala
28089	GGTT	G	0.9979905	ORF8	p.Gly66_Ser67delinsAla
28099	C	T	0.999482	ORF8	p.Ser69Leu
28270	TA	T	0.966583	intergenic_region	n.28271delA
28310	C	T	0.99883	N	p.Pro13Ser
28881	G	T	0.9991505	N	p.Arg203Met
29402	G	T	0.9993105	N	p.Asp377Tyr
29742	G	T	0.9988675	ORF10-CHR_END	n.29742G>T

APPLICATIONS

Infectivity assay, viral growth, neutralisation assay.

DEPOSITOR

Original virus (passage 2) received from Dr Kevin Bewley, UK Health Security Agency, Medical Interventions Group, Porton Down, UK.
Passage 3 virus grown and characterised by CFAR.

ACKNOWLEDGMENTS

Acknowledgment for publications should read "The following reagent was obtained from the Centre For AIDS Reagents, NIBSC, UK: Kappa (B.1.617.1 lineage) (#101032), thanks to the contribution of Dr Kevin Bewley".

User Ref: 101032	Version: 1.0	Version Date: 07/02/2022
Latest version of document available at: Q-DOCS		Date Printed: 17/02/2022 16:17
Document ID: 9230	Page 2 of 4	Issue Status: Published

MATERIAL SAFETY SHEET

Physical properties (at room temperature)			
Physical appearance	Yellow/Pink, liquid		
Fire hazard	None		
Chemical properties			
Stable	Yes	Corrosive:	No
Hygroscopic	No	Oxidising:	No
Flammable	No	Irritant:	No
Other: Live SARS-CoV-2. It is the responsibility of the end user to seek local biosafety approval for the storage and handling of the material in their workplace			
Handling: CAUTION - This preparation is not for administration to humans or animals in the human food chain. This preparation is hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective clothing, gloves and use within ACDP3 or higher facility.			
Toxicological properties			
Effects of inhalation:	Likelihood of Coronavirus infection		
Effects of ingestion:	Likelihood of Coronavirus infection		
Effects of skin absorption:	Not established, avoid contact with skin		
Suggested First Aid			
Inhalation	Seek medical advice		
Ingestion	Seek medical advice		
Contact with eyes	Wash with copious amounts of water. Seek medical advice.		
Contact with skin	Wash thoroughly with water.		
Action on Spillage and Method of Disposal			
Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.			

User Ref: 101032	Version: 1.0	Version Date: 07/02/2022
Latest version of document available at: Q-DOCS		Date Printed: 17/02/2022 16:17
Document ID: 9230	Page 3 of 4	Issue Status: Published

User Ref: 101032	Version: 1.0	Version Date: 07/02/2022
Latest version of document available at: Q-DOCS		Date Printed: 17/02/2022 16:17
Document ID: 9230	Page 4 of 4	Issue Status: Published